We are maintaining a Hold rating on Larimar Therapeutics (NASDAQ:LRMR), with the caveat that we may begin accumulating shares if the stock continues to drop further.The company is developing ...

Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDTBALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage ...

BALA CYNWYD, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

JonesResearch analyst Catherine Novack reiterates a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target after the company reported initial data from a Phase 2 study for nomlabofusp ...

Larimar said that the dose-ascending study showed that daily subcutaneous injections of CTI-1601, at 50 mg and 100 mg doses, produced frataxin levels in peripheral tissues that were at the same ...

Positive data from Larimar Therapeutics, Inc.'s phase 2 study on nomlabofusp for Friedreich's Ataxia suggests growth in the global market. Click for my LRMR update.

Larimar Therapeutics Inc has a consensus price target of $19.6 based on the ratings of 11 analysts. The high is $26 issued by Guggenheim on March 25, 2025.The low is $10 issued by Baird on March ...

Larimar CEO Carole Ben-Maimon, M.D., said the company believes its complete response to the FDA will enable CTI-1601’s return to the clinic.

Larimar held its breath for over a year, but the FDA finally gave the biotech a green light to continue trials of its lead asset, which is for Friedreich’s ataxia.

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being ...